Pulmonary Vasoreactivity Test Response Prediction Model (AVT Response Predictor)

Clinical calculation support · Verify results before clinical use

Patient and haemodynamic data

Enter baseline right-heart catheterization measurements. Add post-AVT measurements only when available.

Clinical decision support

Patient characteristics

Subtype is recorded for context; it does not generate an unvalidated response probability.

Baseline haemodynamics

Use a reliable wedge pressure measurement from right-heart catheterization.

Measurements during acute vasoreactivity testing (optional)

Enter both mPAP and CO to classify the response. If PAWP during AVT is left blank, baseline PAWP is assumed for the displayed PVR calculation; this assumption should be reviewed clinically.

Clinical interpretation

Pulmonary vasoreactivity testing is performed during right-heart catheterization to identify a subset of patients with PAH who may benefit from high-dose calcium-channel blocker therapy. It should be performed and interpreted in an experienced pulmonary hypertension centre.

Current adult acute-response definition

A positive response is a reduction in mPAP of at least 10 mmHg to an absolute mPAP of 40 mmHg or less, with cardiac output increased or unchanged.

Scope and limitations

  • This tool calculates PVR and applies the current haemodynamic response definition to the supplied values.
  • It does not estimate pre-test probability: the original point system and probability bands were not supported by a verifiable validated model.
  • Routine AVT for identifying candidates for calcium-channel blockers is recommended for idiopathic, heritable, and drug-associated PAH, not all PAH subtypes.
  • Historical criteria should not be treated as interchangeable with current guideline criteria.
  • Measurement quality, shunts, wedge-pressure reliability, and the clinical context can materially affect interpretation.

References

Humbert M, Kovacs G, Hoeper MM, et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618–3731. DOI: 10.1093/eurheartj/ehac237.Official guideline / DOI
Sitbon O, Humbert M, Jaïs X, et al.Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111. DOI: 10.1161/CIRCULATIONAHA.104.488486.Publication DOI
Rich S, Kaufmann E, Levy PS.The effect of high doses of calcium-channel blockers on survival in patients with primary pulmonary hypertension. N Engl J Med. 1992;327:76–81. DOI: 10.1056/NEJM199207093270203.Publication DOI
Clinical disclaimer: This calculator is an educational and decision-support aid, not an autonomous diagnostic or treatment tool. It must not replace right-heart catheterization standards, expert interpretation, current guidelines, or individualized clinical judgement. A positive acute response alone does not establish long-term calcium-channel blocker responsiveness.